Phathom Pharmaceuticals Provides Update on FDA Litigation

The FDA established a public docket seeking comments on legal and regulatory questions arising from BDR Pharmaceuticals’ litigation challenging the agency’s rejection of its ANDA for VOQUEZNA. The dispute follows the FDA’s June 6, 2025 decision granting Phathom’s citizen petition and recognizing 10 years of new chemical entity exclusivity through May 3, 2032; comments are due November 23, 2026.

Analysis

The key market change is a wider range of possible outcomes, not a change in generic-entry timing today: opening a comment docket is procedural and does not itself rescind FDA’s prior exclusivity determination. But it gives the challenge a public venue and may keep the issue alive through the November 23 comment deadline and subsequent agency or court action. For PHAT, the risk is concentrated: an earlier-than-expected generic path could pressure branded pricing and demand before the stated exclusivity date, while continued protection preserves the opportunity to monetize the product without that specific generic threat. The second-order risk is commercial behavior: uncertainty alone can make prescribers, distributors, or payers more cautious about committing to a branded product, though the size of that effect is unverified. Over days, headline-driven volatility may dominate; over 1–3 months, comments and litigation developments are the catalysts; over 6–18 months, the economic impact depends on whether FDA or a court changes the path to generic approval. The contrarian point is that a docket is not an adverse ruling, so treating it as immediate loss of exclusivity would overstate the news. Conversely, the company’s favorable prior FDA decision is not a guarantee against a changed agency or judicial outcome. Verify PHAT’s product-level revenue dependence, current ANDA litigation schedule, and options liquidity/ implied volatility before sizing exposure.

Key Decisions for Investors

• Do not trade this as immediate generic entry. Avoid chasing a PHAT move solely on the docket announcement; reassess after the comment deadline and any substantive FDA or court filing.
• For existing PHAT exposure, consider a limited, defined-risk put spread only if option liquidity and premium are acceptable; the hedge thesis is a widening legal-risk discount, not an assumption that exclusivity has already been lost.
• Treat any agency reversal, court order affecting the ANDA rejection, or accelerated generic approval pathway as a thesis-negative catalyst. Continued FDA support for the prior exclusivity position and no adverse court action would weaken the bearish case.
• Before making a directional position, verify product-level sales contribution and the litigation calendar. Without those, the likely magnitude of earnings sensitivity and the appropriate hedge size cannot be established.